488 related articles for article (PubMed ID: 26747273)
1. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
Qian CN; Tan MH; Yang JP; Cao Y
Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
[TBL] [Abstract][Full Text] [Related]
2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
3. [Tumor angiogenesis: recent progress and remaining challenges].
Feige JJ
Bull Cancer; 2010 Nov; 97(11):1305-10. PubMed ID: 21051315
[TBL] [Abstract][Full Text] [Related]
4. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
5. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis in cancer - general pathways and their therapeutic implications.
Dimova I; Popivanov G; Djonov V
J BUON; 2014; 19(1):15-21. PubMed ID: 24659637
[TBL] [Abstract][Full Text] [Related]
7. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
8. Tumor vasculature: a sally port for inhibiting cancer cell spreading.
Qian CN; Pezzella F
Cancer Commun (Lond); 2018 Aug; 38(1):52. PubMed ID: 30075743
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic approaches for targeting tumor angiogenesis.
Linkous AG; Yazlovitskaya EM
Anticancer Res; 2012 Jan; 32(1):1-12. PubMed ID: 22213282
[TBL] [Abstract][Full Text] [Related]
10. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
11. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
Cao Y; Liu Q
Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
15. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.
Simon T; Gagliano T; Giamas G
Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910
[TBL] [Abstract][Full Text] [Related]
16. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
De Bock K; Cauwenberghs S; Carmeliet P
Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
[TBL] [Abstract][Full Text] [Related]
17. Molecular and cellular regulators of cancer angiogenesis.
Goh PP; Sze DM; Roufogalis BD
Curr Cancer Drug Targets; 2007 Dec; 7(8):743-58. PubMed ID: 18220534
[TBL] [Abstract][Full Text] [Related]
18. Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed.
Qin L; Bromberg-White JL; Qian CN
Adv Cancer Res; 2012; 113():191-239. PubMed ID: 22429856
[TBL] [Abstract][Full Text] [Related]
19. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
20. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]